Explore Currently Enrolling Genentech and Roche Clinical Trials in Oncology

Search for clinical trials by making selections below.

Tumor Type View All

Breast Gastrointestinal Genitourinary Gynecologic Hematology Lung Melanoma Solid Tumor

Phase

III II I

Molecule*

Select...
Antibody-drug conjugate (RG6109) Antibody-drug conjugate (RG6148) Anti-MUC16 TDC (RG7882) Anti-TIGIT MAb (MTIG7192A, RG6058) Atezolizumab (anti-PDL1 MAb) (RG7446) BET inhibitor (TEN-010, RG6146) Bevacizumab (anti-VEGF Mab) CD20 TCB (RG6026) CD20 TDB (RG7828) CEA TCB (RG7802) Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ChK1 inhibitor (GDC-0575, RG7741) Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) Codrituzumab (anti–glypican-3 MAb) (GC33, RG7686) Emactuzumab (anti–CSF-1R MAb) (RG7155) Entrectinib FAP-DR5 biMAb (RG7386) FAP-IL2v FP (RG7461) Glypican-3/CD3 biMAb (CHU) Idasanutlin (MDM2 antagonist) (RG7388) Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) Monoclonal antibody (RG6160) Monoclonal antibody (RG6194) Obinutuzumab Pan-RAF inhibitor (RG6185) Personalized cancer vaccine (RG6180) PI3K inhibitor (GDC-0077, RG6114) Polatuzumab vedotin (anti-CD79b ADC) (RG7596) Raf/MEK dual inhibitor Selective estrogen receptor degrader (SERD[3]) (GDC-9545, RG6171) Selicrelumab (anti-CD40 MAb) (RG7876) Taselisib (PI3K inhibitor) (GDC-0032, RG7604) Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601)

US Region

International

Region

Select...
Clear All
View Results
Expand +

Tumor Type: Hematology, Solid Tumor

Phase: PHASE I

Region:

Molecule:

For more information about recruiting clinical trials, please call the Trial Information Support Line for US Clinical Trial information at 888-662-6728 or visit ClinicalTrials.gov.
Email your search results to yourself.
Clear All
View Results
Tumor Type Phase Molecule* Location Study Contact
Tumor
Type
Phase Molecule* Location
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FL NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) FL
NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) MA NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) MA
NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) TX NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Atezolizumab (anti-PDL1 MAb) (RG7446) TX
NCT02926833—A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) FR NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) FR
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IT NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IT
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MA NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MA
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NC NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NC
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NY NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NY
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) TX NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Hematology II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421), Idasanutlin (MDM2 antagonist) (RG7388), Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) TX
NCT02670044—A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab AU NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab AU
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab AZ NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab AZ
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab CO NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab CO
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab DE NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab DE
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab KR NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab KR
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab KY NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab KY
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab MN NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab MN
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab NC NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab NC
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab NZ NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab NZ
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab PA NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab PA
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab RI NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab RI
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab VA NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab VA
NCT02624986—A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) DE NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) DE
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IL NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IL
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KR NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KR
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KY NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KY
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NY NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NY
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NZ NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NZ
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) PA NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) PA
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) WA NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology II, I Idasanutlin (MDM2 antagonist) (RG7388), Obinutuzumab, Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) WA
NCT03135262—A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Antibody-drug conjugate (RG6109) CA NCT03298516—A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
Hematology I Antibody-drug conjugate (RG6109) CA
NCT03298516—A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
Tumor
Type
Phase Molecule* Location
Hematology I Antibody-drug conjugate (RG6109) CO NCT03298516—A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
Hematology I Antibody-drug conjugate (RG6109) CO
NCT03298516—A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
Tumor
Type
Phase Molecule* Location
Hematology I Antibody-drug conjugate (RG6109) CT NCT03298516—A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
Hematology I Antibody-drug conjugate (RG6109) CT
NCT03298516—A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
Tumor
Type
Phase Molecule* Location
Hematology I Antibody-drug conjugate (RG6109) NY NCT03298516—A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
Hematology I Antibody-drug conjugate (RG6109) NY
NCT03298516—A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) AL NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) AL
NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) AR NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) AR
NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) CT NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) CT
NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) GA NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) GA
NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) MA NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) MA
NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) MI NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) MI
NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) MO NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) MO
NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) TX NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) TX
NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) UT NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) UT
NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) WA NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446) WA
NCT02431208—A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) CA NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) CA
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) CA NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) CA
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) CT NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) CT
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) KR NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) KR
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) MO NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) MO
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) NY NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) NY
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) PA NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) PA
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) TN NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) TN
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) TX NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) TX
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) WA NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Hematology I Atezolizumab (anti-PDL1 MAb) (RG7446), CD20 TDB (RG7828) WA
NCT02500407—A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146) AU NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hematology I BET inhibitor (TEN-010, RG6146) AU
NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146) CA NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hematology I BET inhibitor (TEN-010, RG6146) CA
NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146) FL NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hematology I BET inhibitor (TEN-010, RG6146) FL
NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146) GA NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hematology I BET inhibitor (TEN-010, RG6146) GA
NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146) GB NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hematology I BET inhibitor (TEN-010, RG6146) GB
NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146) MA NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hematology I BET inhibitor (TEN-010, RG6146) MA
NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146) NC NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hematology I BET inhibitor (TEN-010, RG6146) NC
NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146) NY NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hematology I BET inhibitor (TEN-010, RG6146) NY
NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146) OK NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Hematology I BET inhibitor (TEN-010, RG6146) OK
NCT03068351—Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU
NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA
NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) DK NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) DK
NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) ES NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) ES
NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NC NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NC
NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NY NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I BET inhibitor (TEN-010, RG6146), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NY
NCT03255096—A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Monoclonal antibody (RG6160) AU NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Hematology I Monoclonal antibody (RG6160) AU
NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Tumor
Type
Phase Molecule* Location
Hematology I Monoclonal antibody (RG6160) AZ NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Hematology I Monoclonal antibody (RG6160) AZ
NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Tumor
Type
Phase Molecule* Location
Hematology I Monoclonal antibody (RG6160) CA NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Hematology I Monoclonal antibody (RG6160) CA
NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Tumor
Type
Phase Molecule* Location
Hematology I Monoclonal antibody (RG6160) CA NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Hematology I Monoclonal antibody (RG6160) CA
NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Tumor
Type
Phase Molecule* Location
Hematology I Monoclonal antibody (RG6160) CO NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Hematology I Monoclonal antibody (RG6160) CO
NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Tumor
Type
Phase Molecule* Location
Hematology I Monoclonal antibody (RG6160) PA NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Hematology I Monoclonal antibody (RG6160) PA
NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Tumor
Type
Phase Molecule* Location
Hematology I Monoclonal antibody (RG6160) TN NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Hematology I Monoclonal antibody (RG6160) TN
NCT03275103—Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab ES NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab ES
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab GA NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab GA
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab GB NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab GB
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab MI NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab MI
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab MO NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab MO
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab NY NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab NY
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab TX NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab TX
NCT02600897—A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AZ NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AZ
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CT NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CT
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) FL NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) FL
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) GA NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) GA
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IT NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IT
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KY NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) KY
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MI NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MI
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NJ NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NJ
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) PA NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) PA
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) TX NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Hematology I Obinutuzumab, Polatuzumab vedotin (anti-CD79b ADC) (RG7596), Rituximab, Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) TX
NCT02611323—A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) AZ NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) AZ
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) ES NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) ES
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) FL NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) FL
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) IL NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) IL
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MO NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MO
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) NY NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) NY
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) OK NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) OK
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TN NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TN
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TX NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Hematology I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TX
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AZ NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AZ
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CH NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CH
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CT NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CT
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) DE NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) DE
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IL NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) IL
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MA NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MA
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MA NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MA
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NL NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NL
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NY NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NY
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) OR NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) OR
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) TN NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) TN
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) TX NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) TX
NCT02966782—A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
Tumor
Type
Phase Molecule* Location
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) WA NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Hematology I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) WA
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AR NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AR
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AZ NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AZ
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CA NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CA
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CA NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CA
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) DE NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) DE
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) ES NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) ES
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) FL NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) FL
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) FR NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) FR
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) GB NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) GB
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) IL NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) IL
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) IT NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) IT
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) MA NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) MA
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) NY NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) NY
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) PA NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) PA
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) TX NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) TX
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) AR NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) AR
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) AU NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) AU
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CT NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CT
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) ES NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) ES
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) FR NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) FR
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) KR NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) KR
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) MA NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) MA
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) MD NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) MD
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) TN NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) TN
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel CO NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel CO
NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel CT NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel CT
NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel DC NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel DC
NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel JP NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel JP
NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel KR NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel KR
NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel MA NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel MA
NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel MN NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel MN
NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel NC NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel NC
NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel NY NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel NY
NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel TN NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel TN
NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel TW NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel TW
NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel WI NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Bevacizumab (anti-VEGF Mab), Capecitabine, Paclitaxel WI
NCT02715531—A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) CA NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) CA
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) CH NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) CH
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) CT NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) CT
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) DK NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) DK
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ES NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ES
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) NL NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) NL
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) NY NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) NY
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) TN NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) TN
NCT02350673—A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) CT NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) CT
NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) ES NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) ES
NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) FR NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) FR
NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) MA NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) MA
NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) NY NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) NY
NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) AZ NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) AZ
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) GB NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) GB
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NY NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NY
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) OR NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) OR
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) AL NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) AL
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) AZ NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) AZ
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) CA NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) CA
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) DK NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) DK
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) ES NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) ES
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) FR NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) FR
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) NL NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) NL
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) BE NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) BE
NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) ES NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) ES
NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) FR NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) FR
NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Bevacizumab (anti-VEGF Mab), Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) CA NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
Solid Tumor I Bevacizumab (anti-VEGF Mab), Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) CA
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Bevacizumab (anti-VEGF Mab), Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) DK NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
Solid Tumor I Bevacizumab (anti-VEGF Mab), Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) DK
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Bevacizumab (anti-VEGF Mab), Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) ES NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
Solid Tumor I Bevacizumab (anti-VEGF Mab), Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) ES
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Bevacizumab (anti-VEGF Mab), Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) NL NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
Solid Tumor I Bevacizumab (anti-VEGF Mab), Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) NL
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Entrectinib CA NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Solid Tumor I Entrectinib CA
NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Tumor
Type
Phase Molecule* Location
Solid Tumor I Entrectinib CO NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Solid Tumor I Entrectinib CO
NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Tumor
Type
Phase Molecule* Location
Solid Tumor I Entrectinib GA NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Solid Tumor I Entrectinib GA
NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Tumor
Type
Phase Molecule* Location
Solid Tumor I Entrectinib IL NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Solid Tumor I Entrectinib IL
NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Tumor
Type
Phase Molecule* Location
Solid Tumor I Entrectinib MA NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Solid Tumor I Entrectinib MA
NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Tumor
Type
Phase Molecule* Location
Solid Tumor I Entrectinib MN NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Solid Tumor I Entrectinib MN
NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Tumor
Type
Phase Molecule* Location
Solid Tumor I Entrectinib MO NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Solid Tumor I Entrectinib MO
NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Tumor
Type
Phase Molecule* Location
Solid Tumor I Entrectinib NY NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Solid Tumor I Entrectinib NY
NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Tumor
Type
Phase Molecule* Location
Solid Tumor I Entrectinib OH NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Solid Tumor I Entrectinib OH
NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Tumor
Type
Phase Molecule* Location
Solid Tumor I Entrectinib OR NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Solid Tumor I Entrectinib OR
NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Tumor
Type
Phase Molecule* Location
Solid Tumor I Entrectinib PA NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Solid Tumor I Entrectinib PA
NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Tumor
Type
Phase Molecule* Location
Solid Tumor I Entrectinib TN NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Solid Tumor I Entrectinib TN
NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Tumor
Type
Phase Molecule* Location
Solid Tumor I Entrectinib TN NCT03330990—Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
Solid Tumor I Entrectinib TN
NCT03330990—Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
Tumor
Type
Phase Molecule* Location
Solid Tumor I Entrectinib TX NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Solid Tumor I Entrectinib TX
NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Tumor
Type
Phase Molecule* Location
Solid Tumor I Entrectinib UT NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Solid Tumor I Entrectinib UT
NCT02650401—Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Tumor
Type
Phase Molecule* Location
Solid Tumor I Idasanutlin (MDM2 antagonist) (RG7388) CO NCT03362723—A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Solid Tumor I Idasanutlin (MDM2 antagonist) (RG7388) CO
NCT03362723—A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Idasanutlin (MDM2 antagonist) (RG7388) CT NCT03362723—A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Solid Tumor I Idasanutlin (MDM2 antagonist) (RG7388) CT
NCT03362723—A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Idasanutlin (MDM2 antagonist) (RG7388) MO NCT03362723—A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Solid Tumor I Idasanutlin (MDM2 antagonist) (RG7388) MO
NCT03362723—A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Idasanutlin (MDM2 antagonist) (RG7388) NV NCT03362723—A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Solid Tumor I Idasanutlin (MDM2 antagonist) (RG7388) NV
NCT03362723—A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Idasanutlin (MDM2 antagonist) (RG7388) OK NCT03362723—A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Solid Tumor I Idasanutlin (MDM2 antagonist) (RG7388) OK
NCT03362723—A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Idasanutlin (MDM2 antagonist) (RG7388) TN NCT03362723—A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Solid Tumor I Idasanutlin (MDM2 antagonist) (RG7388) TN
NCT03362723—A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Idasanutlin (MDM2 antagonist) (RG7388) TX NCT03362723—A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Solid Tumor I Idasanutlin (MDM2 antagonist) (RG7388) TX
NCT03362723—A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Idasanutlin (MDM2 antagonist) (RG7388) VA NCT03362723—A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Solid Tumor I Idasanutlin (MDM2 antagonist) (RG7388) VA
NCT03362723—A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) CA NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) CA
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) ES NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) ES
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) FR NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) FR
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) GB NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) GB
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) MA NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) MA
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) NY NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) NY
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) TN NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) TN
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I RO6874281, Trastuzumab AZ NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Solid Tumor I RO6874281, Trastuzumab AZ
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Solid Tumor I RO6874281, Trastuzumab CA NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Solid Tumor I RO6874281, Trastuzumab CA
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Solid Tumor I RO6874281, Trastuzumab CO NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Solid Tumor I RO6874281, Trastuzumab CO
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Solid Tumor I RO6874281, Trastuzumab DK NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Solid Tumor I RO6874281, Trastuzumab DK
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Solid Tumor I RO6874281, Trastuzumab ES NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Solid Tumor I RO6874281, Trastuzumab ES
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Solid Tumor I RO6874281, Trastuzumab FR NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Solid Tumor I RO6874281, Trastuzumab FR
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Solid Tumor I RO6874281, Trastuzumab GB NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Solid Tumor I RO6874281, Trastuzumab GB
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Solid Tumor I RO6874281, Trastuzumab IT NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Solid Tumor I RO6874281, Trastuzumab IT
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Solid Tumor I RO6874281, Trastuzumab NL NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Solid Tumor I RO6874281, Trastuzumab NL
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Solid Tumor I RO6874281, Trastuzumab NY NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Solid Tumor I RO6874281, Trastuzumab NY
NCT02627274—A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) AZ NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) AZ
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) ES NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) ES
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) FL NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) FL
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) IL NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) IL
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MO NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MO
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) NY NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) NY
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) OK NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) OK
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TN NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TN
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TX NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TX
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Solid Tumor I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) AU
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Tumor
Type
Phase Molecule* Location
Solid Tumor I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Solid Tumor I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CA
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Tumor
Type
Phase Molecule* Location
Solid Tumor I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CH NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Solid Tumor I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CH
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Tumor
Type
Phase Molecule* Location
Solid Tumor I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Solid Tumor I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) CO
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Tumor
Type
Phase Molecule* Location
Solid Tumor I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MA NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Solid Tumor I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) MA
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Tumor
Type
Phase Molecule* Location
Solid Tumor I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NL NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Solid Tumor I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) NL
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Tumor
Type
Phase Molecule* Location
Solid Tumor I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) TN NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Solid Tumor I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) TN
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Tumor
Type
Phase Molecule* Location
Solid Tumor I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) WA NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Solid Tumor I Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601) WA
NCT03236857—A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
1 of 267 clinical trials
1-4 of 267 clinical trials
ClickTap on the NCT numbers above to visit ClinicalTrials.gov for further details about each trial, including eligibility criteria, primary and secondary outcome measures, and contacts and locations.
This website is intended for US healthcare professionals and contains information on investigational compounds and drug uses that have not been approved by the FDA. Click "OK" if you are a healthcare professional and wish to proceed.
CancelOK
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
CancelContinue
The list of international studies is not comprehensive; only international studies that also include actively enrolling US sites are listed.

Click "OK" if you wish to proceed.
CancelOK